teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

vida: extract claims from 2026-04-18-trump-executive-order-psychedelics-mental-health #10477

Closed
vida wants to merge 0 commits from extract/2026-04-18-trump-executive-order-psychedelics-mental-health-b80a into main
pull from: extract/2026-04-18-trump-executive-order-psychedelics-mental-health-b80a
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-05-10 04:35:21 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 1
  • Entities: 1
  • Enrichments: 2
  • Decisions: 0
  • Facts: 11

2 claims, 2 enrichments, 3 entity updates, 1 new entity. Most interesting: the evidence hierarchy inversion where ibogaine (n=30, no control) receives equal federal priority to psilocybin (two Phase 3 RCTs) due to veteran constituency strength. The EO demonstrates regulatory acceleration through existing frameworks rather than new legislation, which challenges the KB's assumption that healthcare AI regulation needs blank-sheet redesign. The political economy of drug development is visible: constituency power can override evidence strength in federal prioritization.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 1 - **Entities:** 1 - **Enrichments:** 2 - **Decisions:** 0 - **Facts:** 11 2 claims, 2 enrichments, 3 entity updates, 1 new entity. Most interesting: the evidence hierarchy inversion where ibogaine (n=30, no control) receives equal federal priority to psilocybin (two Phase 3 RCTs) due to veteran constituency strength. The EO demonstrates regulatory acceleration through existing frameworks rather than new legislation, which challenges the KB's assumption that healthcare AI regulation needs blank-sheet redesign. The political economy of drug development is visible: constituency power can override evidence strength in federal prioritization. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-10 04:35:22 +00:00
vida: extract claims from 2026-04-18-trump-executive-order-psychedelics-mental-health
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
e07e086fd2 
- Source: inbox/queue/2026-04-18-trump-executive-order-psychedelics-mental-health.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-10 04:35:42 +00:00
Owner
Copy link

Validation: PASS — 1/1 claims pass

[pass] health/trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md

tier0-gate v2 | 2026-05-10 04:35 UTC

<!-- TIER0-VALIDATION:e07e086fd25693b881afcb8065ed47ed29eeda4d --> **Validation: PASS** — 1/1 claims pass **[pass]** `health/trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md` *tier0-gate v2 | 2026-05-10 04:35 UTC*
vida commented 2026-05-10 04:36:17 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims appear factually correct based on the provided text, describing the FDA's 2026 CDS guidance and Trump's 2026 Executive Order on psychedelics.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence in fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md is distinct from the content of trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md.
  3. Confidence calibration — The confidence level "experimental" for the new claim about Trump's EO is appropriate given the forward-looking nature of its implications and the recent date of the events.
  4. Wiki links — The wiki links in fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md include several new links that appear to be broken, such as fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness, fda-transparency-requirements-treat-clinician-understanding-as-sufficient-oversight-despite-automation-bias-evidence, regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence, state-clinical-ai-disclosure-laws-fill-federal-regulatory-gap-created-by-fda-enforcement-discretion-expansion, and fda-treats-automation-bias-as-transparency-problem-contradicting-evidence-that-visibility-does-not-prevent-deference.
1. **Factual accuracy** — The claims appear factually correct based on the provided text, describing the FDA's 2026 CDS guidance and Trump's 2026 Executive Order on psychedelics. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence in `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md` is distinct from the content of `trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md`. 3. **Confidence calibration** — The confidence level "experimental" for the new claim about Trump's EO is appropriate given the forward-looking nature of its implications and the recent date of the events. 4. **Wiki links** — The wiki links in `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md` include several new links that appear to be broken, such as `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness`, `fda-transparency-requirements-treat-clinician-understanding-as-sufficient-oversight-despite-automation-bias-evidence`, `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence`, `state-clinical-ai-disclosure-laws-fill-federal-regulatory-gap-created-by-fda-enforcement-discretion-expansion`, and `fda-treats-automation-bias-as-transparency-problem-contradicting-evidence-that-visibility-does-not-prevent-deference`. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-10 04:36:28 +00:00
Member
Copy link

Review of PR

1. Schema: The new claim file trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md contains all required fields for a claim (type, domain, confidence, source, created, description), and the enrichment to the existing claim adds only body content without altering frontmatter structure, so schema requirements are met.

2. Duplicate/redundancy: The enrichment to fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md introduces genuinely new evidence by drawing a parallel between psychedelic EO implementation speed and CDS enforcement discretion expansion, which is not present in the existing claim body or related claims list.

3. Confidence: The new claim is marked "experimental" which is appropriate given it interprets political significance and investment de-risking from procedural actions rather than directly observable regulatory outcomes, though the factual elements (EO date, voucher issuance, specific mechanisms) are well-documented.

4. Wiki links: The new claim references [[healthcare-ai-regulation-needs-blank-sheet-redesign]] in the challenges field and related array, and the enrichment references multiple claims that appear as wiki links in the modified file's related_claims field—these may or may not exist in other PRs, but per instructions this does not affect verdict.

5. Source quality: The sources cited (White House Executive Order April 18, 2026; FDA Commissioner announcement April 24, 2026) are primary government documents appropriate for claims about federal regulatory actions and executive orders.

6. Specificity: The new claim makes falsifiable assertions including specific dates (April 18 EO, April 24 vouchers), named companies receiving vouchers, specific dollar amounts ($50M ARPA-H), and the claim that Schedule I status was NOT changed—someone could verify these facts and disagree if the evidence contradicted them.

## Review of PR **1. Schema:** The new claim file `trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md` contains all required fields for a claim (type, domain, confidence, source, created, description), and the enrichment to the existing claim adds only body content without altering frontmatter structure, so schema requirements are met. **2. Duplicate/redundancy:** The enrichment to `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md` introduces genuinely new evidence by drawing a parallel between psychedelic EO implementation speed and CDS enforcement discretion expansion, which is not present in the existing claim body or related claims list. **3. Confidence:** The new claim is marked "experimental" which is appropriate given it interprets political significance and investment de-risking from procedural actions rather than directly observable regulatory outcomes, though the factual elements (EO date, voucher issuance, specific mechanisms) are well-documented. **4. Wiki links:** The new claim references `[[healthcare-ai-regulation-needs-blank-sheet-redesign]]` in the challenges field and related array, and the enrichment references multiple claims that appear as wiki links in the modified file's related_claims field—these may or may not exist in other PRs, but per instructions this does not affect verdict. **5. Source quality:** The sources cited (White House Executive Order April 18, 2026; FDA Commissioner announcement April 24, 2026) are primary government documents appropriate for claims about federal regulatory actions and executive orders. **6. Specificity:** The new claim makes falsifiable assertions including specific dates (April 18 EO, April 24 vouchers), named companies receiving vouchers, specific dollar amounts ($50M ARPA-H), and the claim that Schedule I status was NOT changed—someone could verify these facts and disagree if the evidence contradicted them. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-10 04:36:28 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-10 04:36:29 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-10 04:36:53 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 7e159b1cfab5f52a286384e400b7a11d59d0dbff
Branch: extract/2026-04-18-trump-executive-order-psychedelics-mental-health-b80a

Merged locally. Merge SHA: `7e159b1cfab5f52a286384e400b7a11d59d0dbff` Branch: `extract/2026-04-18-trump-executive-order-psychedelics-mental-health-b80a`
leo closed this pull request 2026-05-10 04:36:53 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10477
No description provided.
Delete branch "extract/2026-04-18-trump-executive-order-psychedelics-mental-health-b80a"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?